key: cord-1047723-all65v4q
authors: Freeman, Esther E.; McMahon, Devon E.; Desai, Seemal R.; Fox, Lindy P.
title: Reply To “Comment on ‘The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries’”
date: 2021-02-25
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.02.056
sha: 7af7b594b5b43a2a42ed859f7ddb73bc950c88ca
doc_id: 1047723
cord_uid: all65v4q

nan

19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries." 1 29

The authors bring up important concerns which we note in our limitations, including lack of photo/biopsy 30 evidence of COVID-19 dermatologic manifestations and limited laboratory confirmation. These issues are a result of the nature of registry-based case entry and poor availability laboratory COVID-19 testing early 32 in the pandemic.

The authors also note the lack of racial/ethnic diversity in our registry, which we agree is 34 concerning and may partially be due to deficiencies in providers recognizing COVID-19 dermatologic test positivity/negativity in mild disease. 5 The seven publications from the registry to date must be viewed 57 through the lens of the public health emergency, as the scientific community moved from no known skin 58 findings associated with COVID-19 to characterizing the cutaneous manifestations and their potential 59 implications within just a few months.

We 

COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 69 countries

Absence of images of skin of colour in publications of 71 COVID-19 skin manifestations

and rapid harmonization across dermatologic COVID-19 registries

Timing of PCR and antibody 77 testing in patients with COVID-19-associated dermatologic manifestations